

Press release – For immediate release July 25, 2022 – 5:45 pm CEST

## Financial communication schedule for the second half of 2022

**Sophia Antipolis, France** – Median Technologies (ALMDT), announces the publication date for its 2022 half year results and its Q3, 2022 business performance:

Publication	Date	
<ul><li> 2022 H1 results</li><li> Q3, 2022 business performance</li></ul>	Oct 20, 2022*	

\*Distribution after the close of trading



**About Median Technologies: About Median Technologies:** Median Technologies provides innovative imaging solutions and services to advance healthcare for everyone. We harness the power of medical images by using the most advanced Artificial Intelligence technologies, to increase the accuracy of diagnosis and treatment of many cancers and other metabolic diseases at their earliest stages and provide insights into novel therapies for patients. Our iCRO solutions for medical image analysis and management in oncology trials and iBiopsy<sup>®</sup>, our AI-powered software as medical device

help biopharmaceutical companies and clinicians to bring new treatments and diagnose patients earlier and more accurately. This is how we are helping to create a healthier world.

Founded in 2002, based in Sophia-Antipolis, France, with a subsidiary in the US and another one in Shanghai, Median has received the label "Innovative company" by the BPI and is listed on Euronext Growth market (Paris). FR0011049824– ticker: ALMDT. Median is eligible for the French SME equity savings plan scheme (PEA-PME), is part of the Enternext® PEA-PME 150 index and has been awarded the Euronext European Rising Tech label. For more information: <u>www.mediantechnologies.com</u>

## Contacts

Median Technologies	Press - ALIZE RP	Investors - ACTIFIN
Emmanuelle Leygues	Caroline Carmagnol	Ghislaine Gasparetto
Head of Corporate Marketing & Financial Communications	+33 6 64 18 99 59	+33 6 21 10 49 24
+33 6 10 93 58 88	median@alizerp.com	ggasparetto@actifin.fr
emmanuelle.leygues@mediantechnologies.com		